Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On March 15, 2017, Aclaris Therapeutics, Inc. (the Registrant)
issued a press release announcing its financial results for the
quarter and year ended December 31, 2016, as well as information
regarding a conference call to discuss these financial results. A
copy of this press release is furnished herewith as Exhibit 99.1
to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Item 2.02, and Exhibit 99.1 hereto, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any of the Registrants filings under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, regardless of any
incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit |
|
|
Number |
ExhibitDescription |
|
99.1 |
Press Release, dated March 15, 2017, Aclaris Therapeutics |
2
About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Recent Trading Information
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) closed its last trading session down -0.65 at 30.48 with 90,153 shares trading hands.